Experts from Syneos Health and UDG Healthcare comment on the current state of the global pharma contract sales market – which is estimated to reach $9.48bn by 2023.
QuintilesIMS may potentially divest its contract sales business – which would improve the company’s overall profitability and enable it to focus on growing other aspects of the organization.